Indivior Pharmaceuticals, Inc. INDV
Set alert
At close · Oct 30
After hours · Oct 30, 7:40 PM ET
- YTD
- -1.42%
- 1 year
- +21.42%
- Open
- 34.78
- Prev close
- 35.25
- Mkt cap
- 4.17B
- Vol
- 4.61M
- Avg vol
- 2.40M
- EPS
- 2.79
- P/E
- 12.68
- Div yield
- 0.00%
More statistics
- Low
- 34.62
- High
- 36.48
- Forward P/E
- 7.84
- Beta
- 0.00
- Short ratio
- 3.89
- Inst. own
- 104.85%
- Dividend
- 0.00
- Ex-div date
- Oct 29, 2026
- Earnings
- Feb 25, 2027
- 50-d avg
- 35.24
- 200-d avg
- 35.66
- 1y target
- 49.50
3M chart
Events in this range
- Aug 3, 2026Earnings: 1.15; estimate 0.869; surprise 32.34%
- Aug 5, 2026Rating: Barclays · Overweight → Overweight
- Oct 28, 2026Rating: Barclays · Overweight → Overweight
- Oct 29, 2026Earnings: 1.32; estimate 1.06; surprise 24.53%
- Oct 30, 2026Dividend: 8.13
Signals (21)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 2026 | 2 days ago |
| SMA: Bullish | Oct 29, 2026 | 3 days ago |
| MACD: Buy Signal | Oct 26, 2026 | 6 days ago |
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| SMA: Bullish | Oct 22, 2026 | 1 week ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 14, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bullish | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Sep 25, 2026 | 1 month ago |
| SMA: Bullish | Sep 24, 2026 | 1 month ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 22, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 15, 2026 | 1 month ago |
| RSI: Oversold | Sep 8, 2026 | 1 month ago |
| RSI: Oversold | Aug 28, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 20, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 18, 2026 | 2 months ago |
| SMA: Bearish | Aug 3, 2026 | 3 months ago |
Key statistics
- Market cap
- 4.17B
- Enterprise value
- 4.36B
- Trailing P/E
- 12.67
- Forward P/E
- 7.84
- PEG ratio
- 0.00
- Price / sales
- 3.04
- Price / book
- 0.00
- EPS (TTM)
- 2.79
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 32.75%
- Revenue (TTM)
- 1.37B
- Revenue growth
- 13.40%
- Free cash flow
- 245.12M
- Total cash
- 305.00M
- Total debt
- 501.00M
- Return on equity
- 0.00%
- Shares outstanding
- 118.04M
- Short % of float
- 9.48%
- 50-day average
- 35.24
- 200-day average
- 35.66
Analyst view
Consensus: strong buy
- Target (low)
- 45.00
- Target (mean)
- 49.50
- Target (high)
- 53.00
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate 1.22.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | 0.986 | — | — | — |
| Oct 29, 2026 | Sep 30, 2026 | 1.06 | 1.32 | +0.26 | +24.53% |
| Aug 3, 2026 | Jun 30, 2026 | 0.869 | 1.15 | +0.28 | +32.34% |
| Apr 30, 2026 | Mar 31, 2026 | 0.64 | 0.96 | +0.32 | +50.00% |
| Feb 26, 2026 | Dec 31, 2025 | 0.65 | 0.82 | +0.17 | +26.15% |
| Oct 30, 2025 | Sep 30, 2025 | 0.38 | 0.72 | +0.34 | +89.47% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | Barclays | main | Overweight | Overweight |
| Aug 5, 2026 | Barclays | main | Overweight | Overweight |
| Jun 18, 2026 | Barclays | init | — | Overweight |
| Jan 12, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 31, 2025 | Piper Sandler | reit | Overweight | Overweight |
| Oct 30, 2025 | HC Wainwright & Co. | main | Buy | Buy |
About Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- indivior.com
News
- Indivior Pharmaceuticals Affirms FY2026 Sales Guidance of $1.295B-$1.365B vs $1.334B Est
- Indivior Q3 Adj. EPS $1.32 Beats $1.12 Estimate, Sales $356.000M Beat $329.350M Estimate
- Indivior Reports Third Quarter 2026 Financial Results
- Barclays Maintains Overweight on Indivior Pharmaceuticals, Raises Price Target to $45
- Indivior (INDV) Projected to Announce Earnings on Thursday
- Indivior to Report Third Quarter 2026 Financial Results
- Indivior PLC (NASDAQ:INDV) Stock Has Average Price Target of $45.17
- Financial Contrast: Sonoma Pharmaceuticals (NASDAQ:SNOA) versus Indivior (NASDAQ:INDV)
- Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
- Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Your note
Sign in to keep a note on INDV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BlackRock, Inc. | — | Holding | Jun 26, 2025 | 8,269,109 |
| Crossley (Mark) | — | Bought | Mar 16, 2025 | 350,927 |
| Deerfield Partners LLC | — | Annual Return | Feb 27, 2025 | 6,567,399 |
| Kairos Capital Management, LLC | — | Annual Return | Feb 27, 2025 | 12,457,514 |
| Kalia (Vishal) | — | Bought | Mar 2, 2025 | 139,836 |
| Madison Avenue Partners LP | — | Increase | Mar 10, 2025 | 6,464,040 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 15.85% | 18,709,432 | 661.19M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 6.42% | 7,572,287 | 267.60M | Jun 29, 2026 |
| Oaktree Capital Management LP | 5.19% | 6,127,212 | 216.54M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.66% | 5,495,486 | 194.21M | Jun 29, 2026 |
| State Street Corporation | 4.23% | 4,992,071 | 176.42M | Jun 29, 2026 |
| Fuller & Thaler Asset Management Inc. | 3.91% | 4,615,816 | 163.12M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.95% | 7,028,347 | 248.38M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.28% | 3,873,712 | 136.90M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.62% | 3,097,715 | 109.47M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.37% | 2,797,172 | 98.85M | Jun 29, 2026 |
| Capitol Series Trust-FullerThaler Behavioral Small-Cap Growth Fund | 1.82% | 2,152,304 | 76.06M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.36% | 1,609,803 | 56.89M | Jun 29, 2026 |